Glycogen synthase kinase-3 regulation of urinary concentrating ability

Current Opinion in Nephrology and Hypertension

Volumn 21, Issue 5, 2012, Pages 541-546

  Rao, Reena ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Aquaporin 2; Cyclooxygenase; Glycogen synthase kinase 3; Nephrogenic diabetes insipidus; Prostaglandin; Vasopressin

Indexed keywords

ADENYLATE CYCLASE; AQUAPORIN 2; AQUAPORIN 3; AQUAPORIN 4; CYCLIC AMP; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; VASOPRESSIN;

CELL PROLIFERATION; DIABETES INSIPIDUS; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; FLUID BALANCE; GENE DELETION; HUMAN; KIDNEY COLLECTING TUBULE; KIDNEY CONCENTRATING CAPACITY; POLYURIA; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; WATER DEPRIVATION; WATER TRANSPORT;

ANIMALS; AQUAPORIN 2; BIOLOGICAL TRANSPORT; GLYCOGEN SYNTHASE KINASE 3; HUMANS; KIDNEY TUBULES, COLLECTING; SIGNAL TRANSDUCTION; VASOPRESSINS;

EID: 84865439698     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32835571d4     Document Type: Review

References (59)

1. Embi N, Rylatt DB, Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 1980; 107:519-527.
2. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multitasking kinase. J Cell Sci 2003; 116:1175-1186. (Pubitemid 36410657)
3. Woodgett JR, Force T. Unique and overlapping functions of GSK-3 isoforms in cellular differentiation, proliferation, and cardiovascular development. J Biol Chem 2008; 284:9643-9647.
4. Cai Z, Zhao Y, Zhao B. Roles of glycogen synthase kinase 3 in Alzheimer's disease. Curr Alzheimer Res 2012. [Epub ahead of print]
5. Cheng H, Woodgett J, Maamari M, Force T. Targeting GSK-3 family members in the heart: a very sharp double-edged sword. J Mol Cell Cardiol 2011; 51:607-613.
6. MacAulay K, Woodgett JR. Targeting glycogen synthase kinase-3 (GSK-3) in the treatment of type 2 diabetes. Expert Opin Ther Targets 2008; 12:1265-1274.
7. Ali A, Hoeflich KP, Woodgett JR. Glycogen synthase kinase-3: properties, functions, and regulation. Chem Rev 2001; 101:2527-2540. (Pubitemid 35373033)
8. Kaidanovich-Beilin O, Woodgett JR. GSK-3: functional insights from cell biology and animal models. Frontiers Mol Neurosci 2011; 4:40.
9. Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/factor a. EMBO J 1990; 9:2431-2438.
10. Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007; 408:297-315.
11. Jope RS. Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 2003; 24:441-443. (Pubitemid 37088166)
12. De Sarno P, Li X, Jope RS. Regulation of akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 2002; 43:1158-1164. (Pubitemid 36009369)
13. Chalecka-Franaszek E, Chuang DM. Lithium activates the serine/threonine kinase akt-1 and suppresses glutamate-induced inhibition of akt-1 activity in neurons. Proc Natl Acad Sci USA 1999; 96:8745-8750. (Pubitemid 29354862)
14. Kockeritz L, Doble B, Patel S, Woodgett JR. Glycogen synthase kinase-3: an overview of an over-achieving protein kinase. Curr Drug Targets 2006; 7:1377-1388. (Pubitemid 44718298)
15. Hoeflich KP, Luo J, Rubie EA, et al. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 2000; 406: 86-90. (Pubitemid 30460216)
16. Kerkela R, Kockeritz L, Macaulay K, et al. Deletion of GSK-3beta in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation. J Clin Invest 2008; 118:3609-3618.
17. MacAulay K, Doble BW, Patel S, et al. Glycogen synthase kinase 3alphaspecific regulation of murine hepatic glycogen metabolism. Cell Metab 2007; 6:329-337. (Pubitemid 47450185)
18. Rao R, Patel S, Hao C, et al. GSK3beta mediates renal response to vasopressin by modulating adenylate cyclase activity. J Am Soc Nephrol 2010; 21:428-437.
19. Kjaersgaard G, Madsen K, Marcussen N, et al. Tissue injury after lithium treatment in human and rat postnatal kidney involves glycogen synthase kinase-3beta-positive epithelium. Am J Physiol Renal Physiol 2012; 302: F455-F465.
20. Dugo L, Collin M, Allen DA, et al. Gsk-3beta inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat. Crit Care Med 2005; 33:1903-1912. (Pubitemid 41306508)
21. Wang Z, Havasi A, Gall J, et al. Gsk3{beta} promotes apoptosis after renal ischemic injury. J Am Soc Nephrol 2010; 21:284-294.
22. Yao HB, Shaw PC, Wong CC, Wan DC. Expression of glycogen synthase kinase-3 isoforms in mouse tissues and their transcription in the brain. J Chem Neuroanat 2002; 23:291-297. (Pubitemid 34606866)
23. Matsumura Y, Uchida S, Rai T, et al. Transcriptional regulation of aquaporin-2 water channel gene by cAMP. J Am Soc Nephrol 1997; 8:861-867. (Pubitemid 27427230)
24. Umenishi F, Narikiyo T, Vandewalle A, Schrier RW. cAMP regulates vasopressin-induced AQP2 expression via protein kinase A-independent pathway. Biochim Biophys Acta 2006; 1758:1100-1105. (Pubitemid 44373864)
25. Yasui M, Zelenin SM, Celsi G, Aperia A. Adenylate cyclase-coupled vasopressin receptor activates AQP2 promoter via a dual effect on cre and AP1 elements. Am J Physiol 1997; 272:F443-F450.
26. Fushimi K, Sasaki S, Marumo F. Phosphorylation of serine 256 is required for cAMP-dependent regulatory exocytosis of the aquaporin-2 water channel. J Biol Chem 1997; 272:14800-14804. (Pubitemid 27251748)
27. Kortenoeven ML, Li Y, Shaw S, et al. Amiloride blocks lithium entry through the sodium channel thereby attenuating the resultant nephrogenic diabetes insipidus. Kidney Int 2009; 76:44-53.
28. Kortenoeven ML, Schweer H, Cox R, et al. Lithium reduces aquaporin-2 transcription independent of prostaglandins. Am J Physiol Cell Physiol 2012; 302:C131-C140.
29. Nielsen J, Hoffert JD, Knepper MA, et al. Proteomic analysis of lithium-induced nephrogenic diabetes insipidus: mechanisms for aquaporin 2 down-regulation and cellular proliferation. Proc Natl Acad Sci USA 2008; 105:3634-3639. (Pubitemid 351723604)
30. Rao R, Zhang MZ, Zhao M, et al. Lithium treatment inhibits renal GSK-3 activity and promotes cyclooxygenase 2-dependent polyuria. Am J Physiol Renal Physiol 2005; 288:F642-F649. (Pubitemid 40381730)
31. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996; 93:8455-8459. (Pubitemid 26269579)
32. Grunfeld JP, Rossier BC. Lithium nephrotoxicity revisited. Nat Rev Nephrol 2009; 5:270-276.
33. Timmer RT, Sands JM. Lithium intoxication. J Am Soc Nephrol 1999; 10:666-674. (Pubitemid 29117649)
34. Stone KA. Lithium-induced nephrogenic diabetes insipidus. J Am Board Fam Pract 1999; 12:43-47. (Pubitemid 29238699)
35. O'Brien WT, Klein PS. Validating GSK3 as an in vivo target of lithium action. Biochem Soc Trans 2009; 37:1133-1138.
36. Ryves WJ, Harwood AJ. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun 2001; 280:720-725. (Pubitemid 32924489)
37. Zhang F, Phiel CJ, Spece L, et al. Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem 2003; 278:33067-33077. (Pubitemid 37055753)
38. Rao R, Hao CM, Breyer MD. Hypertonic stress activates glycogen synthase kinase 3beta-mediated apoptosis of renal medullary interstitial cells, suppressing an NFkappaB-driven cyclooxygenase-2-dependent survival pathway. J Biol Chem 2004; 279:3949-3955. (Pubitemid 38198978)
39. Bendz H, Sjodin I, Aurell M. Renal function on and off lithium in patients treated with lithium for 15 years or more. A controlled, prospective lithium-withdrawal study. Nephrol Dial Transplant 1996; 11:457-460. (Pubitemid 26093740)
40. Jia Z, Wang H, Yang T. Mice lacking mPGES-1 are resistant to lithiuminduced polyuria. Am J Physiol Renal Physiol 2009; 297:F1689-F1696.
41. Christensen BM, Kim YH, Kwon TH, Nielsen S. Lithium treatment induces a marked proliferation of primarily principal cells in rat kidney inner medullary collecting duct. Am J Physiol Renal Physiol 2006; 291:F39-F48. (Pubitemid 43945934)
42. Christensen BM, Marples D, Kim YH, et al. Changes in cellular composition of kidney collecting duct cells in rats with lithium-induced NDI. Am J Physiol Cell Physiol 2004; 286:C952-C964. (Pubitemid 38543824)
43. Kwon TH, Laursen UH, Marples D, et al. Altered expression of renal AQPs and Na(+) transporters in rats with lithium-induced NDI. Am J Physiol Renal Physiol 2000; 279:F552-F564.
44. Marples D, Christensen S, Christensen EI, et al. Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla. J Clin Invest 1995; 95:1838-1845.
45. Orloff J, Handler JS, Bergstrom S. Effect of prostaglandin (PGE-1) on the permeability response of toad bladder to vasopressin, theophylline and adenosine 30,50-monophosphate. Nature 1965; 205:397-398.
46. Lipson L, Hynie S, Sharp G. Effect of prostaglandin E-1 on osmotic water flow and sodium transport in the toad bladder. Ann N Y Acad Sci 1971; 180:260-277.
47. Grantham JJ, Orloff J. Effect of prostaglandin E1 on the permeability response of the isolated collecting tubule to vasopressin, adenosine 30,50-monophosphate, and theophylline. J Clin Invest 1968; 47:1154-1161.
48. Hao CM, Breyer MD. Physiological regulation of prostaglandins in the kidney. Annu Rev Physiol 2008; 70:357-377. (Pubitemid 351738184)
49. Harris RC, Breyer MD. Physiological regulation of cyclooxygenase-2 in the kidney. Am J Physiol Renal Physiol 2001; 281:F1-F11.
50. Guan Y, Chang M, Cho W, et al. Cloning, expression, and regulation of rabbit cyclooxygenase-2 in renal medullary interstitial cells. Am J Physiol 1997; 273:F18-F26.
51. Harris RC, McKanna JA, Akai Y, et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994; 94:2504-2510. (Pubitemid 24379628)
52. Kotnik P, Nielsen J, Kwon TH, et al. Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am J Physiol Renal Physiol 2005; 288:F1053-F1068. (Pubitemid 40569771)
53. Christensen S, Kusano E, Yusufi AN, et al. Pathogenesis of nephrogenic diabetes insipidus due to chronic administration of lithium in rats. J Clin Invest 1985; 75:1869-1879. (Pubitemid 15237796)
54. Goldberg H, Clayman P, Skorecki K. Mechanism of Li inhibition of vasopressin-sensitive adenylate cyclase in cultured renal epithelial cells. Am J Physiol 1988; 255:F995-F1002.
55. Hozawa S, Holtzman EJ, Ausiello DA. cAMP motifs regulating transcription in the aquaporin 2 gene. Am J Physiol 1996; 270:C1695-C1702.
56. Jackson BA, Edwards RM, Dousa TP. Lithium-induced polyuria: effect of lithium on adenylate cyclase and adenosine 30,50-monophosphate phosphodiesterase in medullary ascending limb of Henle's loop and in medullary collecting tubules. Endocrinology 1980; 107:1693-1698. (Pubitemid 11194673)
57. Yamaki M, Kusano E, Tetsuka T, et al. Cellular mechanism of lithium-induced nephrogenic diabetes insipidus in rats. Am J Physiol 1991; 261:F505-F511.
58. Li Y, Shaw S, Kamsteeg EJ, et al. Development of lithium-induced nephrogenic diabetes insipidus is dissociated from adenylyl cyclase activity. J Am Soc Nephrol 2006; 17:1063-1072.
59. Force T, Woodgett JR. Unique and overlapping functions of GSK-3 isoforms in cell differentiation and proliferation and cardiovascular development. J Biol Chem 2009; 284:9643-9647.